Could Intranasal Oxytocin Help Reduce Irritability in Children with Neurodevelopmental Disorders? | Research

The takeaway

A mini-review of 15 pediatric RCTs found that intranasal oxytocin modulates brain areas involved in emotional processing, but inconsistent dosing and small sample sizes have prevented clear conclusions about clinical efficacy.

15 pediatric RCTs reviewed
Despite 15 trials across three neurodevelopmental disorders, mixed results and methodology gaps prevent clear conclusions about oxytocin's clinical benefit

What the researchers found

Across 15 pediatric RCTs in autism spectrum disorder, Prader-Willi syndrome, and Phelan-McDermid syndrome, intranasal oxytocin showed neuroimaging evidence of modulating reward processing and social-emotional brain areas.

However, clinical results were mixed, with changes in irritability mainly documented as adverse events rather than primary outcomes. The review identifies the lack of established pharmacodynamic and pharmacokinetic models for intranasal oxytocin as a key barrier, along with small sample sizes and inconsistent dosing across studies.

Why it matters

Irritability is one of the most common and disabling symptoms in children with neurodevelopmental disorders, yet treatment options are limited. If intranasal oxytocin can be shown to reliably reduce emotional overreactivity through its effects on brain circuits, it could fill a significant therapeutic gap — but only with better-designed trials using consistent dosing and appropriate outcome measures.

How the study worked

Mini-review of 15 randomized controlled trials of intranasal oxytocin in pediatric populations (children with ASD, Prader-Willi syndrome, or Phelan-McDermid syndrome). The review assessed both clinical outcomes and neuroimaging findings related to emotional processing and social behavior.

What this study cannot tell us

Most of the 15 reviewed trials had small sample sizes. Dosing varied substantially across studies, making comparisons difficult. Changes in irritability were primarily captured as adverse events rather than pre-specified primary outcomes, limiting the strength of conclusions about efficacy. The pharmacokinetics of intranasal oxytocin in children remain poorly characterized.

How to read the evidence

This is a mini-review of randomized controlled trials. While the underlying evidence comes from RCTs (a strong design), the small sample sizes, variable dosing, and mixed results across studies limit the overall strength of conclusions.

When this study was published

Published in 2023, this review captures the current state of pediatric intranasal oxytocin research and identifies key gaps for future studies.

The bigger picture

Intranasal oxytocin has been tested in numerous psychiatric conditions with underwhelming clinical results, raising questions about whether the approach works at all. This review argues the problem is not the molecule but the methods — specifically, the absence of pharmacokinetic modeling for intranasal delivery and the failure to match the treatment to the right symptom target. Repositioning oxytocin as an irritability treatment rather than a broad social behavior intervention could be a more productive direction.

Questions still open

What is the optimal dose and duration of intranasal oxytocin for pediatric populations, and does it differ by diagnosis?
Would a trial specifically designed to measure irritability reduction as the primary outcome show clearer benefits?
Can neuroimaging biomarkers predict which children are most likely to respond to intranasal oxytocin?

Common questions

Why is irritability a promising target for oxytocin treatment in children?

Irritability involves overactivation of brain areas that process emotions and threats. Oxytocin has been shown in brain imaging studies to reduce activity in these same areas. This mechanism-target match makes irritability a more logical focus than broad social behavior improvement, where oxytocin's effects have been inconsistent.

Is intranasal oxytocin safe for children?

Across the 15 reviewed trials, intranasal oxytocin was generally well-tolerated in pediatric populations. However, the review notes that irritability was sometimes reported as an adverse event, and the long-term safety profile in developing brains is not yet well established. More research is needed, especially on optimal dosing.

Read the original research

Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural Responses: A Mini Review.

Journal of psychiatry and brain science, 8(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Sorenson, Kennet; Kendall, Emilee; Grell, Hannah; Kang, Minjoo; Shaffer, Christopher; Hwang, Soonjo. (2023). Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural Responses: A Mini Review.. Journal of psychiatry and brain science, 8(4). https://doi.org/10.20900/jpbs.20230008